share_log

Senti Biosciences | 8-K: Current report

Senti Biosciences | 8-K: Current report

Senti Biosciences | 8-K：重大事件
美股SEC公告 ·  07/16 16:08
Moomoo AI 已提取核心信息
On July 16, 2024, Senti Biosciences, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol SNTI, reported the entry into an amended and restated ChEF purchase agreement with Chardan Capital Markets LLC. This agreement pertains to Senti Biosciences' existing $50 million equity facility and includes updated volume weighted average price purchase mechanics to allow for Intraday VWAP Purchases. The details of the amended agreement were summarized in the company's Form 8-K filing with the SEC, with the full text of the agreement attached as Exhibit 10.1. Senti Biosciences, identified as an emerging growth company, has also elected not to use the extended transition period for complying with new or revised financial accounting standards. The company's CEO, Timothy Lu, M.D., Ph.D., signed the SEC filing on the same day, affirming the company's compliance with the Securities Exchange Act of 1934.
On July 16, 2024, Senti Biosciences, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol SNTI, reported the entry into an amended and restated ChEF purchase agreement with Chardan Capital Markets LLC. This agreement pertains to Senti Biosciences' existing $50 million equity facility and includes updated volume weighted average price purchase mechanics to allow for Intraday VWAP Purchases. The details of the amended agreement were summarized in the company's Form 8-K filing with the SEC, with the full text of the agreement attached as Exhibit 10.1. Senti Biosciences, identified as an emerging growth company, has also elected not to use the extended transition period for complying with new or revised financial accounting standards. The company's CEO, Timothy Lu, M.D., Ph.D., signed the SEC filing on the same day, affirming the company's compliance with the Securities Exchange Act of 1934.
2024年7月16日，纳斯达克资本市场上市的德拉华公司Senti Biosciences，交易标的为SNTI，与Chardan Capital Markets LLC签署修订后的ChEF购买协议。该协议涉及Senti Biosciences现有的5000万美元股权计划，并包括更新的成交量加权平均价格购买机制，以允许当日VWAP购买。修订后的协议的详细条款在公司提交的8-K文件中总结，协议的完整文本作为附件10.1附加在文件中。作为新兴成长型公司，Senti Biosciences还选择不使用延长过渡期的选项以符合新的或修订后的财务会计准则。公司的CEO Timothy Lu万.D.，Ph.D.于同一天签署了SEC文件，确认公司遵守1934年证券交易法。
2024年7月16日，纳斯达克资本市场上市的德拉华公司Senti Biosciences，交易标的为SNTI，与Chardan Capital Markets LLC签署修订后的ChEF购买协议。该协议涉及Senti Biosciences现有的5000万美元股权计划，并包括更新的成交量加权平均价格购买机制，以允许当日VWAP购买。修订后的协议的详细条款在公司提交的8-K文件中总结，协议的完整文本作为附件10.1附加在文件中。作为新兴成长型公司，Senti Biosciences还选择不使用延长过渡期的选项以符合新的或修订后的财务会计准则。公司的CEO Timothy Lu万.D.，Ph.D.于同一天签署了SEC文件，确认公司遵守1934年证券交易法。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息